An analysis of electronic health records in eight states showed that during last year’s respiratory virus season, newly approved vaccines for respiratory syncytial virus (RSV) were effective in preventing associated hospitalizations and more severe outcomes in adults ages 60 and older.

Adjusted vaccine efficacy in immunocompetent individuals was 80% (95% CI 71-85) against RSV-related hospitalizations, 81% (95% CI 71-85) against associated critical illness (intensive care unit (ICU) admission, death, or mortality). 95 GA 52-92) reached. Amanda Payne reported 77% (95% CI 70-83) opposition to RSV-related emergency room visits: PhD and colleagues from the CDC.

According to the findings, the vaccines also showed significant benefit in high-risk groups. Lancet.

Among immunocompromised adults hospitalized with RSV-like illness, vaccine effectiveness was 73% (95% CI 48-85). In immunocompetent adults, effectiveness against RSV-related hospitalizations and emergency department visits was similar regardless of age:

• 60-74 years: 81% and 75% respectively
• ≥75 years: 79% and 78%

Payne said the clinical trials that led to vaccine approvals “were not really powered to evaluate the effectiveness of the RSV vaccine in these high-risk populations, so adults 75 and older or adults with immunocompromising conditions.” MedPage Today.

In addition to being effective against severe outcomes, “we were able to show that the vaccines also work in adults aged 75 and over and in people with compromised immune systems,” he added.

Real-world data helped inform Updated recommendations from the CDC Payne said of RSV vaccines that it “clarifies who will benefit most from the vaccine.” “These current recommendations are for all adults ages 75 and older who have not already received a dose of RSV vaccine, and then for those ages 60 to 74 who have certain underlying medical conditions who have not yet received a dose of the vaccine, they would receive that dose of vaccine.”

One accompanying commentDr. from the University of Rochester Medical Center in New York. “What is remarkable is how closely vaccine efficacy against hospitalization or emergency room encounters matches clinical trial efficacy estimates against lower respiratory tract diseases,” Angela Branche said.

The data also answers another important question: “a decrease in vaccine-induced protection over the season, which is refuted by similar point estimates at 14-59 days compared to at least 60 days after vaccination with overlapping confidence intervals,” Branche wrote. .

“This was exactly what was needed to help us understand how effective these vaccines are in a real-world setting,” Branche said. MedPage Today.

The data allows practitioners to say with confidence that a patient is 80% less likely to be hospitalized with RSV if they receive their vaccine.

Branche noted that the study grouped all immunocompromised individuals together.

“Having said that, it was a bit of a surprise how good the efficacy was in immunocompromised patients,” he said. “You might expect productivity to be a little bit lower, and it was encouraging and maybe a little surprising that it was pretty similar.”

The study found that estimates of vaccine effectiveness were similar by product type. During operation only Arexvy And Abrysvo Approved and available. A third RSV vaccine has since been approved for use in adults: mResvia.

Regarding hospitalizations among immunocompetent older adults, Payne and colleagues reported that vaccine efficacy was 83% for the GSK vaccine and 73% for the Pfizer vaccine. Vaccine effectiveness in emergency department visits was determined as 77% and 79%, respectively.

The study examined 28,271 hospitalizations and 36,521 emergency room visits for RSV-like illness among immunocompetent adults and 8,435 hospitalizations for RSV-like illness among adults with immunocompromising conditions.

“I hope the data we show in this article helps increase confidence that vaccines will help prevent serious disease,” Payne said, “and we will continue to monitor more in the future.”

Payne and colleagues also noted that researchers could not rule out the possibility that patients with RSV-positive encounters may have had an encounter for other reasons; which “could have lowered vaccine efficacy estimates.”

Additionally, misclassification of vaccination status was possible, there was variation in RSV testing from region to region, not all underlying conditions may have been captured, and some variables were inadequately captured in electronic health records (e.g., smoking history), they noted. Additionally, the findings may not be generalizable to the entire US population.